PubMed Health⌕ Search

Biomedical subjects

E C Tocus

Publications and source records attributed to E C Tocus.

8 recordsLinked to original sources

The effects of chronic treatment and withdrawal of CNS depressants on aggressive behavior.

Young adult CD-1 male mice were housed in individual cages throughout the study. Groups of 10 to 20 mice were given gradually increasing doses of delta-9-tetrahydrocannabinol (THC) at 6.25 to 25 mg/kg i.p., trifluoperazine (TFP) at 6 to 12 mg/kg p.o., phenobarbital sodium (PS) at 20 to 35 mg/kg p.o., morphine sulfate (MS) at 5 to 20 mg/kg i.p., methaqualone (MQ) 10 to 20 mg/kg p.o. or chlordiazepoxide (CDP) 10 to 25 mg/kg p.o. over four to six weeks to develop tolerance of these drugs. Following the development of tolerance, the drugs were withdrawn. On the fourth day of withdrawal, a young (3-4 weeks old) male mouse was introduced into the cage. When the intensity of the attack was measured by the percentage of animals that killed the intruder within four hours. The results indicated 0 to 4 percent in the controls, 50-54 percent for THC, 50 percent for TFP, 42 percent for PS and 57 percent for MS. In contrast, no killing behavior was exhibited by these mice after treatment with MQ or CDP. These data suggest that enhanced aggressive behavior, elicited by withdrawal from certain psychotropic drugs, may be measured by the killing (muricidal) behavior of isolated mice.

Aggression↗

Food and Drug Administration's requirements for markers.

Three basic principles must be satisfied when a substance is being considered for human ingestion: The composition of the product must be consistent within certain limits over a specific period of time. It must not produce irreversible harm or unacceptable side effects. When taken as indicated, it must produce the effect that is claimed and intended. Specific requirements for markers will depend on the marker selected. There are regulations for use of radioactive substances as tracers in drugs. Markers might also be subject to regulations for a new drug or combination drug or might be a substance generally recognized as safe. If the marker is included as an excipient in the drug, the associated requirements for excipients would apply. Any assay methods for detecting the marker must be validated.

Clinical Trials as Topic↗

The effect of tripelennamine alone and in combination with opiates to produce antinociception in mice.

Antinociception (ANTI) was assessed in male CD-1 mice by a modification of Haffner's tail clamp procedure. Studies revealed that tripelennamine (Tp) alone produced antinociception (ANTI) in mice and also caused potentiation when combined with morphine (M) or nalbuphene (NB). Naloxone (Nx) only partially blocked the effect of Tp, but fully blocked M. Although atropine (At) had no intrinsic ANTI activity, it enhanced that of Tp but not M. Histamine (Hm) had no intrinsic ANTI activity, nor did it interact with either Tp or M. The partial abolition of Tp ANTI, in contrast to complete blockade of M effects with Nx, appears to indicate that Tp can stimulate the opiate receptor as well as another receptor for ANTI at a different locus. The combination of Tp with various opiates may have considerable abuse potential.

Analgesia↗